Tumor gene expression analysis - PI3K Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

ABSTRACT: Of the 142 patients enrolled in Study CHRONOS-1, an open-label, single-arm, Phase II study evaluating the efficacy and safety of single-agent copanlisib in patients with relapsed or refractory, indolent B-cell lymphoma (NCT01660451; Part B), 96 archival formalin-fixed paraffin-embedded tumor tissues were collected under relevant consent and available for tumor macro-dissection, mRNA extraction and gene expression profiling using Affymetrix GeneChip Gene ST 1.0 Arrays (AltheaDx, Inc., San Diego, CA, USA). Of these, only 78 samples were with high quality and passed Affymetrix positive versus negative controls AUC ≥ 0.62. Affymetrix CEL files were processed with RMA (R package affy) using a custom CDF from Brainarray (version 20.0.0). 71 patients with indolent non-Hodgkin lymphoma (iNHL), in

ORGANISM(S): Homo sapiens

SUBMITTER: Henrik Seidel 

PROVIDER: E-MTAB-6088 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress